The use of ovarian needle in patients with breast cancer

Navigation:Home > Internal Oncology > Mammary Cancer > The use of ovarian needle in patients with breast cancer

In Chinese, the median age of onset of breast cancer than small European countries nearly 10 years old, a lot of young breast cancer patient

Content

In Chinese, the median age of onset of breast cancer than small European countries nearly 10 years old, a lot of young breast cancer patients and family needs, and in recent years with SOFT& subgroup analysis released the results of the TEXT clinical research, many patients involves the use of eggs in the nest of needle chemotherapy during and after chemotherapy.

Here is a simple introduction to the use of ovarian needle,

The ovarian needle, also known as castration, is an analogue of the hormone LHRH in the body. The use of breast cancer patients is mainly divided into two categories:

First, protect the ovaries during chemotherapy. Mainly because chemotherapy drugs on the proliferation of fast metabolism cell killing effect, and premenopausal women every month to have regular menstrual period, the ovary is at a relatively active proliferation and metabolism, so in order to avoid the damage of chemotherapy drugs on ovarian function, we should put the eggs into a nest of proliferation of metabolically inactive organs. While the use of ovary after needle will reduce the proliferation of ovarian metabolism, inhibit ovarian function, so after the use of ovarian needle will appear menopausal symptoms, menstrual cramps are no longer. When the use of chemotherapy can be stopped after the ovarian needle, the majority of menstruation can be gradually restored, usually about half a year, if the follow-up still need to carry out adjuvant endocrine therapy, see second.

Second, endocrine therapy in the process, enhance the effectiveness of endocrine therapy. For Luminal type of breast cancer (also is the need of endocrine therapy for breast cancer), if premenopausal patients, adjuvant therapy can choose only tamoxifen or toremifene, but there have been many clinical studies have demonstrated the efficacy of aromatase inhibitors is better than tamoxifen and aromatase inhibitors, must use in postmenopausal patients therefore, for the part of a high risk of recurrence and metastasis of Luminal breast cancer patients, in order to enhance our strength of treatment and the curative effect of endocrine therapy, usually by needle will develop ovarian hormone level in the body into the postmenopausal state, plus tamoxifen or aromatase inhibitors as ovarian needle plus adjuvant endocrine therapy, so as to further improve the curative effect.

Is the use of a needle of ovary, 28 days subcutaneous injection, the first use of ovarian needle approximately 2 weeks after a period, the theory should be no subsequent menstruation. More than 98% of the patients with ovarian function can be inhibited in postmenopausal women, but there are still a few poor patients, so in patients with ovarian control, needle menopause, while eating endocrine drugs, hormone levels should be reviewed regularly.

 

www.Cure001.comwww.Cure999.com

Cerebral Vascular Disease,Acne,Heart Disease,Deaf,Headache,Std,Condyloma Acuminatum,Fibroid,Pneumonia,Brain Trauma,。 Rehabilitation Blog 

Rehabilitation Blog @ 2017